Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus Recommendation of “Buy” from Analysts

Dyne Therapeutics, Inc. (NASDAQ:DYN) has received an average recommendation of “Buy” from the eight research firms that are currently covering the firm, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $37.75.

A number of analysts recently commented on DYN shares. Chardan Capital increased their price objective on Dyne Therapeutics from $20.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, March 8th. Stifel Nicolaus increased their price target on Dyne Therapeutics from $35.00 to $41.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th. Oppenheimer reiterated an “outperform” rating and set a $47.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, March 26th. Piper Sandler increased their price objective on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, March 6th.

Dyne Therapeutics Trading Down 0.6 %

Shares of NASDAQ DYN opened at $25.31 on Wednesday. The company’s 50-day moving average price is $26.15 and its 200 day moving average price is $18.06. Dyne Therapeutics has a 52 week low of $6.40 and a 52 week high of $30.27. The stock has a market cap of $2.18 billion, a price-to-earnings ratio of -6.42 and a beta of 0.95.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Tuesday, March 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.17). As a group, research analysts expect that Dyne Therapeutics will post -3.25 earnings per share for the current year.

Insider Activity

In related news, major shareholder Venture Fund Xi L.P. Atlas sold 184,501 shares of the company’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $22.57, for a total transaction of $4,164,187.57. Following the completion of the sale, the insider now directly owns 6,631,464 shares of the company’s stock, valued at approximately $149,672,142.48. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, major shareholder Venture Fund Xi L.P. Atlas sold 184,501 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $22.57, for a total transaction of $4,164,187.57. Following the transaction, the insider now directly owns 6,631,464 shares of the company’s stock, valued at approximately $149,672,142.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Susanna Gatti High sold 2,292 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $25.70, for a total transaction of $58,904.40. Following the completion of the sale, the chief operating officer now directly owns 156,800 shares of the company’s stock, valued at approximately $4,029,760. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,875,432 shares of company stock valued at $44,368,530. Company insiders own 20.77% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Fcpm Iii Services B.V. acquired a new position in shares of Dyne Therapeutics in the fourth quarter worth about $81,543,000. Braidwell LP raised its position in shares of Dyne Therapeutics by 32.2% in the 3rd quarter. Braidwell LP now owns 1,821,972 shares of the company’s stock valued at $16,325,000 after purchasing an additional 444,100 shares in the last quarter. Vivo Capital LLC boosted its stake in shares of Dyne Therapeutics by 58.0% during the 1st quarter. Vivo Capital LLC now owns 1,635,136 shares of the company’s stock valued at $46,422,000 after buying an additional 600,000 shares during the last quarter. Armistice Capital LLC grew its position in shares of Dyne Therapeutics by 31.6% during the third quarter. Armistice Capital LLC now owns 1,200,000 shares of the company’s stock worth $10,752,000 after buying an additional 288,000 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. acquired a new stake in Dyne Therapeutics in the fourth quarter valued at $15,758,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.